Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2008.20.2358 on December 1 2008

Journal of Clinical Oncology, Vol 27, No 1 (January 1), 2009: pp. 159
© 2009 American Society of Clinical Oncology.

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sartore-Bianchi, A.
Right arrow Articles by Siena, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sartore-Bianchi, A.
Right arrow Articles by Siena, S.
Related Articles
Right arrowRelated Correspondence
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

CORRESPONDENCE

In Reply

Andrea Sartore-Bianchi, Salvatore Artale

Falck Division of Medical Oncology, Ospedale Niguarda Ca’ Granda, Milan, Italy

Silvio Veronese, Marcello Gambacorta

Division of Pathology, Ospedale Niguarda Ca’ Granda, Milan, Italy

Salvatore Siena

Falck Division of Medical Oncology, Ospedale Niguarda Ca’ Granda, Milan, Italy

We thank Velho et al for their interest in our study, which showed a 95% concordance rate of KRAS and BRAF status between primary and metastatic sites of colorectal carcinomas.1 The authors refer to their previous study, in which they found a lower concordance rate (64%) between lymph node metastases and primary tumors in a cohort of 28 of 250 colorectal cancers.2 Possible explanations for the discrepancy between the two concordance rates may be, first, that our patient series included only patients with stage IV disease and that of Velho et al included patients with stage 0 to IV disease, and second, that in the latter study, KRAS status was not assessed in distant metastatic sites.

In addition to our findings, full concordance of KRAS status between primary tumors and distant metastases,3-5 and between primary tumors and regional lymph nodes,6 has been reported by independent investigators, supporting the notion that detection of a KRAS-activating mutation in either a primary or metastatic site is sufficient to exclude a patient from epidermal growth factor receptor–targeted monoclonal antibody therapies.

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The author(s) indicated no potential conflicts of interest.

NOTES

published online ahead of print at www.jco.org on December 1, 2008

REFERENCES

1. Artale S, Sartore-Bianchi A, Veronese SM, et al: Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 26:4217-4219, 2008[Free Full Text]

2. Oliveira C, Velho S, Moutinho C, et al: KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 26:158-163, 2007[CrossRef][Medline]

3. Losi L, Benhattar J, Costa J: Stability of K-ras mutations throughout the natural history of human colorectal cancer. Eur J Cancer 28A:1115-1120, 1992[CrossRef]

4. Etienne-Grimaldi MC, Formento JL, Francoual M, et al: K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 14:4830-4835, 2008[Abstract/Free Full Text]

5. Al-Mulla F, Going JJ, Sowden ET, et al: Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol 185:130-138, 1998[CrossRef][Medline]

6. Zauber P, Sabbath-Solitare M, Marotta SP, et al: Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. Mol Pathol 56:137-140, 2003[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Correspondence

  • KRAS Mutations and Anti–Epidermal Growth Factor Receptor Therapy in Colorectal Cancer With Lymph Node Metastases
    Sérgia Velho, Carla Oliveira, and Raquel Seruca
    JCO 2009 27: 158-159 [Full Text]



This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sartore-Bianchi, A.
Right arrow Articles by Siena, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sartore-Bianchi, A.
Right arrow Articles by Siena, S.
Related Articles
Right arrowRelated Correspondence
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2009 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online